S2Medical

0.01 SEK

-5.56 %

Less than 1K followers

S2M

First North Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-5.56 %

-32.67 %

-31.31 %

-36.45 %

-43.33 %

-41.88 %

-96.85 %

-99.47 %

-99.81 %

S2Medical operates in the medical technology sector. The company is focused on research and development of various wound healing products. Various products offered include cellulose-based materials and dressings for the healing of burns and chronic wounds. The products are sold under various brands, mainly at a European level. S2Medical was founded in 2013 and is headquartered in Linköping.

Market cap

6.37M SEK

Turnover

210.31 SEK

Revenue

14.36M

EBIT %

-18.54 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

5.6

2026

General meeting '26

21.8

2026

Interim report Q2'26

All

Press releases

ShowingAll content types

Regulatory press release6/20/2024, 8:32 AM

S2Medical AB: Epiprotect® Demonstrates Significantly Lower Infection Risk in Major Pediatric Study

Regulatory press release11/6/2023, 3:09 PM

S2Medical AB (publ) Signs Exclusive Distribution Agreement with Provas Medical Ltd for the Turkish Market

Regulatory press release8/25/2023, 1:30 PM

S2Medical AB: INTERIM REPORT APRIL - JUNE 2023

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release7/5/2023, 6:45 AM

S2Medical AB (publ) announces final outcome in the company's rights issue

Regulatory press release7/4/2023, 8:21 AM

S2Medical AB Secures New Loan Agreement and Aims to be Debt-Free by July 2024

Regulatory press release7/3/2023, 4:26 PM

S2Medical AB: S2Medical (publ) announces preliminary outcome in the company's rights issue

Regulatory press release6/16/2023, 11:45 AM

S2Medical AB (publ) publishes a prospectus regarding the rights issue

Regulatory press release6/8/2023, 3:15 PM

S2Medical AB (publ) signs a manufacturing agreement with a distributor in Saudi Arabia

Regulatory press release5/31/2023, 5:00 PM

S2Medical AB: Interim Report January - March 2023

Regulatory press release5/17/2023, 11:33 AM

S2Medical AB (publ) signs a distribution agreement for the Iranian market

Regulatory press release5/16/2023, 2:45 PM

S2Medical AB: S2Medical wins procurement for wound healing items in the Västra Götaland region

Regulatory press release5/10/2023, 9:34 AM

S2Medical AB: Postponing of publication of the quarterly report for the period January to March 2023

Regulatory press release4/24/2023, 3:09 PM

S2Medical AB: Postponement of publication of annual report

Regulatory press release4/21/2023, 1:37 PM

S2Medical AB: S2Medical wins procurement for wound healing items in the United Arab Emirates worth approximately SEK 3.4 million

Regulatory press release4/13/2023, 9:32 AM

S2Medical AB (publ) signs a distributor agreement in the United Arab Emirates and delivers a record order of the skin substitute Epiprotect worth about SEK 2 million

Regulatory press release3/28/2023, 2:36 PM

S2Medical AB: S2Medical implements a strategic change to reach profitability faster

Regulatory press release3/3/2023, 11:39 AM

S2Medical AB: S2Medical wins procurement for wound healing equipment in Region Halland

Regulatory press release2/22/2023, 2:45 PM

Year-end report January - December 2022 S2Medical AB (publ)

Regulatory press release2/16/2023, 4:44 PM

S2Medical AB: Postponing of publication of the year-end report

Regulatory press release1/2/2023, 4:15 PM

S2Medical AB: Positive outcome when S2Medicals antimicrobial peptides were tested against the multi resistant bacteria that by WHO have been defined as a global health threat

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.